In late January, we sat down with Michael Ward from of IVI's newest members, The Alliance for Aging Research. We are so pleased to partner with such a dynamic organization. Thank you so much for speaking with us today. Could you tell us a little bit about the Alliance for Aging Research? [...]
Author: Jennifer Bright, MPA, Executive Director, IVI For decades, we've known that untreated or poorly treated Major Depressive Disorder (MDD) is an enormous burden on individual patients, our health care system, and our society. Despite having this knowledge, there is much work to do in order to support and optimize cost-effective care for patients suffering [...]
First of Its Kind Depression Model to be Informed by Input from Diverse Advisory Group September 9, 2020 — Alexandria, VA — The Innovation and Value Initiative (IVI) — a non-profit organization dedicated to advancing the science, practice, and use of value assessment in healthcare — today announced a multi-year initiative to build and test [...]
IVI offered comments on ICER's recently released Draft Evidence Report examining the cost-effectiveness of Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis. In addition to commenting on the needs for transparency and the impacts of modeling assumptions on results, IVI's comments raise a broader question about the relevance of the analysis to decision making. IVI writes [...]
PRESS RELEASE: IVI Showcases Recent Research Activities as Part of the Open-Source Value Project at ISPOR EU 2018
Los Angeles, CA – November 13, 2018 – The Innovation and Value Initiative (IVI) – a collaboration dedicated to advancing the science and improving the practice of value assessment in healthcare – will present research at this week’s ISPOR Europe 2018 conference showcasing different elements of the Open-Source Value Project (OSVP) initiative to facilitate assessment [...]
PRESS RELEASE: IVI Discusses the Open-Source Value Project and Its Relevance in Modernizing Cost-Effectiveness Analysis
ISPOR Conference Examines How New Approaches to Value Assessment May Help Move Toward More Informed Pricing Washington, D.C. –- October 19, 2018 -- At the ISPOR Summit 2018, the lead scientific advisor for the Innovation and Value Initiative (IVI) - a collaboration dedicated to advancing the science and improving the practice of value assessment in [...]
Is Using Centralized Value Assessment to Make Centralized Pricing Decisions the Most Effective Path Forward?
The Pink Sheet article described comment letters to HHS’ drug pricing blueprint recommending that cost-effectiveness analyses by ICER could help promote value-based pricing in government-sponsored insurance. While IVI concurs value assessment is noble, worthwhile and needed, IVI cautions about making centralized pricing decisions based on centralized value assessments within the U.S.’s current decentralized health care [...]
PRESS RELEASE: IVI Responds to HHS’ Blueprint Saying Lowering Healthcare Costs Requires Improving Value Assessment
IVI Says Moving Beyond Cost Effectiveness by Evaluating Treatments Based on Unique Patient Characteristics and Preferences is Imperative Los Angeles, CA – July 16, 2018 -- If we are going to truly harness data to lower healthcare costs while accelerating and rewarding innovation that benefits patients, then defining and assessing value in healthcare must [...]
In an op-ed published by Fierce Healthcare, Director of Scientific Communications, Mark Linthicum discusses current shortfalls of value assessment and what is needed to move to value assessment 2.0. Read the full article here.
A new Innovation and Value Initiative (IVI) report found that cost-effectiveness analyses (CEAs) are disproportionately conducted on pharmaceutical interventions compared to other health care treatments. Learn more about what causes this and the potential policy solutions to achieve better overall balance of CEAs across health care interventions. Read more about the project and results here.